Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,439 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,439 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00480987 | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk… | Phase 1 / Phase 2 | terminated | Jun 1, 2007 | M.D. Anderson Cancer Center | Lack of support. | Other (stated, no rule matched) |
| NCT00509600 | Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | Phase 2 | terminated | Jul 31, 2007 | M.D. Anderson Cancer Center | Slow enrollment; study terminated. | Enrollment / accrual |
| NCT01222195 | Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) | Phase 2 | terminated | Oct 18, 2010 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT00962715 | Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon… | Phase 1 / Phase 2 | withdrawn | Aug 20, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00074763 | Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated… | Phase 3 | terminated | Dec 23, 2003 | M.D. Anderson Cancer Center | Terminated due to low recruitment. | Enrollment / accrual |
| NCT00443300 | Effectiveness of Protected Environment Rooms for AML and MDS | — | terminated | Mar 5, 2007 | M.D. Anderson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT00081887 | Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic… | Phase 1 | terminated | Apr 27, 2004 | M.D. Anderson Cancer Center | low accrual | Enrollment / accrual |
| NCT00513305 | Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients… | Phase 3 | terminated | Aug 8, 2007 | Cephalon | Study has been stopped by sponsor decision | Sponsor / business decision |
| NCT00800566 | Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) | Phase 1 | withdrawn | Dec 2, 2008 | M.D. Anderson Cancer Center | Sponsor terminated. | Other (stated, no rule matched) |
| NCT00514189 | Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell… | Phase 1 | terminated | Aug 9, 2007 | M.D. Anderson Cancer Center | Terminated early due to slow accrual. | Enrollment / accrual |
| NCT00960726 | NOV-002 in Myelodysplastic Syndrome (MDS) | Phase 2 | withdrawn | Aug 18, 2009 | M.D. Anderson Cancer Center | Study withdrawn at sponsor request. | Other (stated, no rule matched) |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | Phase 3 | terminated | Aug 9, 2005 | Emergent Product Development Seattle LLC | New sponsor, other treatments available | Other (stated, no rule matched) |
| NCT01029509 | Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes | Phase 1 | terminated | Dec 10, 2009 | M.D. Anderson Cancer Center | Colloborator-Sponsor decision to terminate. | Sponsor / business decision |
| NCT00893997 | PR1 Vaccination in Myelodysplastic Syndrome (MDS) | Phase 2 | terminated | May 6, 2009 | M.D. Anderson Cancer Center | The trial was ended per sponsor due to slow accrual rates. | Enrollment / accrual |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
| NCT00886496 | Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL… | Phase 1 | withdrawn | Apr 23, 2009 | Enzon Pharmaceuticals, Inc. | No participants enrolled. IND withdrawn. | Enrollment / accrual |
| NCT00151736 | Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of… | Phase 2 | terminated | Sep 9, 2005 | Cephalon | not stated | Not stated |
| NCT00253552 | G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders | N/A | terminated | Nov 15, 2005 | OHSU Knight Cancer Institute | Terminated at request of PI as study was outdated. | Other (stated, no rule matched) |
| NCT00570999 | Palifermin After Haploidentical PBSCT(KGF Haplo Allo) | Phase 2 | withdrawn | Dec 11, 2007 | European Society for Blood and Marrow Transplantation | not stated | Not stated |
| NCT00343447 | Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With… | Phase 2 | withdrawn | Jun 23, 2006 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | not stated | Not stated |
| NCT00499889 | Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients | Phase 2 | terminated | Jul 12, 2007 | M.D. Anderson Cancer Center | Support issue. | Other (stated, no rule matched) |
| NCT00019409 | Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in… | Phase 3 | withdrawn | Feb 27, 2004 | National Institutes of Health Clinical Center (CC) | not stated | Not stated |
| NCT00827099 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte… | Phase 2 | terminated | Jan 22, 2009 | Northside Hospital, Inc. | Unacceptable morbidity \& mortality | Other (stated, no rule matched) |
| NCT00402935 | Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer | — | withdrawn | Nov 23, 2006 | Case Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT01066468 | Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and… | Phase 1 | terminated | Feb 10, 2010 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | Phase 1 | withdrawn | Oct 14, 2011 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00074750 | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic… | Phase 1 | terminated | Dec 23, 2003 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT00124748 | Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase…(TOPS) | Phase 3 | terminated | Jul 28, 2005 | Novartis Pharmaceuticals | This study was prematurely discontinued because no improvement was observed in the 800mg dose… | Other (stated, no rule matched) |
| NCT01456182 | Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic… | Phase 1 | withdrawn | Oct 20, 2011 | Afexa Life Sciences Inc | not stated | Not stated |
| NCT00419081 | Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor… | Phase 2 | terminated | Jan 8, 2007 | BioCryst Pharmaceuticals | Issues with Manufacturing | Drug supply |
| NCT00446303 | A Phase II Study of Maintenance With Azacitidine in MDS Patients | Phase 2 | terminated | Mar 12, 2007 | Groupe Francophone des Myelodysplasies | not stated | Not stated |
| NCT00758693 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or… | Phase 2 | withdrawn | Sep 25, 2008 | University of Kentucky | Funding was withdrawn due to insufficient accrual | Enrollment / accrual |
| NCT00504491 | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia(R-CHOP) | Phase 2 | withdrawn | Jul 20, 2007 | CABYC | IMP new owner decision | Other (stated, no rule matched) |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for… | Phase 1 | terminated | May 15, 2007 | M.D. Anderson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | Phase 2 | terminated | May 8, 2009 | European Society for Blood and Marrow Transplantation | Slow recruitment. No safety concerns during this study. | Safety / toxicity |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | Phase 2 | terminated | May 21, 2010 | The Christie NHS Foundation Trust | Potential safety issue of second primary malignancies in patients treated with lenalidomide. | Safety / toxicity |
| NCT00519090 | Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous…(ENEST) | Phase 3 | terminated | Aug 21, 2007 | Novartis Pharmaceuticals | This study was terminated due to limited enrollment. | Enrollment / accrual |
| NCT00918931 | Obatoclax for Systemic Mastocytosis | Phase 2 | terminated | Jun 11, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01011998 | A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) | Phase 2 | withdrawn | Nov 11, 2009 | New Mexico Cancer Research Alliance | Withdrawn due to lack of accrual per Center DSMP, with PI concurrence | Enrollment / accrual |
| NCT00428077 | Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | Phase 2 | terminated | Jan 29, 2007 | OHSU Knight Cancer Institute | Withdrawn because there were no dramatic changes in the main endpoint, as well as low enrollment… | Efficacy / futility |
| NCT00430443 | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML | Phase 1 | terminated | Feb 1, 2007 | Callisto Pharmaceuticals | Participants are no longer being examined or treated. | Other (stated, no rule matched) |
| NCT00915811 | Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients…(FB-ATG) | Phase 2 | terminated | Jun 8, 2009 | King's College Hospital NHS Trust | FB ATG is now a standard for sib allo MDS patients | Other (stated, no rule matched) |
| NCT00839059 | Lenalidomide In Patients With Acute Myeloid Leukemia | Phase 1 | terminated | Feb 9, 2009 | University of Ulm | Results of an interim analysis and a hardly ongoing enrolment in the last 10 months in all six… | Efficacy / futility |
| NCT00002778 | Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With… | Phase 2 | terminated | Jan 27, 2003 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | subject accrual and data analysis is completed. | Enrollment / accrual |
| NCT00003561 | Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase… | Phase 2 | terminated | Mar 22, 2004 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | not stated | Not stated |
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | Phase 2 | terminated | Sep 3, 2007 | CancerCare Manitoba | Terminated due to poor accrual. | Enrollment / accrual |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic… | Phase 2 | terminated | May 18, 2010 | Nevada Cancer Institute | Low enrollment | Enrollment / accrual |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a… | Phase 2 | withdrawn | May 26, 2010 | Nevada Cancer Institute | PI left institution | Investigator |
| NCT00768339 | A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Oct 8, 2008 | Aegera Therapeutics | Slow recruitment | Enrollment / accrual |
| NCT01018069 | AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure… | Phase 2 | terminated | Nov 23, 2009 | Aegera Therapeutics | Failed to reach endpoints | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 7, 2012source: clinicaltrials